Prevalence of Problematic Use of Social Media (PURPLE)

February 28, 2025 updated by: Hospices Civils de Lyon

Prevalence of Problematic Use of Social Media in the General PopuLation

In 2023, French individuals spend an average of two hours per day on social media platforms (SM), primarily Facebook, TikTok, X, YouTube, Instagram, and Snapchat. While social media offers undeniable benefits, it also raises concerns about its impact on mental health and well-being. These impacts remain poorly understood, partly due to the diversity of social media uses and motivations, which do not have uniform effects on health. For instance, studies have shown that "active" use of social media (e.g., content creation) is associated with higher well-being, whereas "passive" use (e.g., content scrolling) is linked to lower well-being.

This challenge in understanding the variety of social media uses and their consequences has direct clinical implications. Clinicians working in pediatrics, child psychiatry, and addiction medicine are increasingly confronted with patients struggling to manage their social media use. However, they lack clear diagnostic criteria to differentiate between normal and problematic use, as well as specific tools tailored to address potential disorders.

Moreover, in France, there is no existing estimate of the proportion of the general population affected by problematic social media use.

This study aims to establish the prevalence of problematic use of social media in France. The investigators hypothesize that the prevalence will be close to 10%, which is the prevalence that has been found in other European countries in previous studies.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Lyon, France, 69003
        • Hospices Civils de Lyon
        • Contact:
        • Principal Investigator:
          • Julia DE TERNAY, Dr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Panel population (probability sample):The first study population will consist of a panel of 3,900 participants provided by the Selvitys Institute. These participants are selected using probability sampling methods to ensure that they are representative of the general French population aged 13 years or older. The selection is based on key demographic characteristics such as age, gender, and geographic location, level of education, ensuring a diverse and balanced sample.

Social media population (non-probability sample):The second study population will consist of individuals who voluntarily respond to the online self-administered questionnaire through recruitment campaigns on social media platforms. This non-probability sample is composed of individuals who actively use social media and are interested in participating. As participation is voluntary, the sample may not fully represent the broader French population but will provide insights into social media users' behavior and experiences

Description

Inclusion Criteria:

  • Aged 13 years or older.
  • Resident in France and French-speaking.
  • Does not object to participating in the study, and, for minors, whose parents also do not object to their participation.

Exclusion Criteria:

  • Unable to understand and complete the questionnaire (e.g., non-French-speaking).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Social media users
All French individuals aged 13 years or older who use social media
An anonymous self-administered online questionnaire hosted on LimeSurvey, lasting approximately 20 minutes, will be completed by participants. A panel of participants representative of the general population will be provided by the Selvitys Institute. In parallel, the self-administered questionnaire will also be distributed via posts on social media platforms (Facebook, YouTube, Instagram, TikTok, Snapchat, and X) over a period of three months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of problematic use of social media.
Time Frame: baseline
Outcome measure: Problematic use will be identified if the participant endorses at least 6 out of 9 items on the French version of the Social Media Addiction Scale. The prevalence of problematic use will be calculated as the number of participants with problematic use divided by the total number of participants.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Julia DE TERNAY, Dr, Hospices Civils de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

July 1, 2025

Study Completion (Estimated)

July 1, 2025

Study Registration Dates

First Submitted

January 20, 2025

First Submitted That Met QC Criteria

January 27, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 28, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 69HCL24_0042
  • 2024-A02539-38 (Other Identifier: ID-RCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Addiction

Clinical Trials on Self-administered survey

Subscribe